NasdaqGS:CRNXPharmaceuticals
Crinetics Pharmaceuticals (CRNX) Stock Looks Overvalued Despite Strong 3 Year Returns
Crinetics Pharmaceuticals has delivered a very strong share price run over the past three years, yet its current valuation screens as expensive on market multiples and the broader checks only give it a mixed score. That combination leaves investors weighing a powerful recent return against signals that the stock is not clearly cheap at today’s price of US$84.75.
Crinetics Pharmaceuticals has returned 428.0% over the past three years, which sets a high bar for any further gains to be...